Increase of dihydrofolate reductase in peripheral blood lymphocytes of rheumatoid arthritis patients treated with low-dose oral methotrexate.
Because of a previously observed plateau of clinical response after long-term methotrexate (MTX) therapy for rheumatoid arthritis (RA), we investigated whether such treatment might lead to acquired resistance to the drug. We studied the activity of dihydrofolate reductase (DHFR) (the target enzyme of MTX) in peripheral blood mononuclear cells of 11 RA patients who had been treated with MTX for a median of 43 months. The enzyme levels were markedly increased compared with levels found in the cells of 6 RA patients treated with other slow-acting drugs. Quantitative dot-blot analysis of DNA from 7 of these patients showed no evidence of DHFR gene amplification. No correlation was observed between increased levels of DHFR and either response to therapy or to the weekly MTX dosage. Phytohemagglutinin-stimulated peripheral blood lymphocytes from 6 patients with increased levels of DHFR showed no evidence of MTX resistance in vitro. The increased DHFR levels may result from binding of MTX to the enzyme, which may block the normal degradation pathways; they do not appear to be a marker of impending drug resistance.
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000201:enzymology*; D004247:DNA / Q000302:isolation & purification; D004351:Drug Resistance; D004361:Drug Tolerance; D005784:Gene Amplification; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects / Q000201:enzymology*; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D013762:Tetrahydrofolate Dehydrogenase / Q000097:blood* / Q000235:genetics
D004247:DNA; D013762:Tetrahydrofolate Dehydrogenase; D008727:Methotrexate